If you're married or divorced, spousal benefits could be key to achieving financial security in retirement.
Financial results for MedMen, one of the country's leading dispensary companies, suggest this market is on the cusp of a major opportunity.
There's been a lot going on over these past couple of months with the cannabis and marijuana industry.
These top marijuana stocks could have market-moving news on deck soon.
The marijuana heavyweight has announced a revolutionary new agreement to create a hub of hemp innovation in New York.
These fast-growing stocks target massive markets that could make them some of the market's best growth stocks.
Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.
The developer of a new cholesterol-lowering treatment is on a path toward commercialization.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
These stocks skyrocketed following exciting announcements.
The robotic-surgery Goliath offered up a rosy outlook at the J. P. Morgan Healthcare Conference this week.
The company's guidance for the coming year suggests soft wine, liquor, and beer sales.
A push into new, recreational marijuana markets is driving significant growth for this maker of pot packaging.
You could be rewarded with breakneck growth this year if you own these three marijuana stocks.
The clinical-stage biotech hopes to tap into what could be a megablockbuster indication.
The pharmaceutical giant is making a big bet on this cancer-drug upstart.
This insulin pump maker launched a revolutionary new treatment option for type 1 patients.
The company's preliminary 2018 results are sparking investor interest.
A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.
Data presented by a competitor increased the risk to its most promising clinical-stage therapy.